Immuno-PET developer ImaginAb has signed a partnership with DongCheng Pharmaceutical Group with the goal of achieving market authorization in China for cancer imaging radiotracers.
ImaginAb's lead candidate is a zirconium-89-labeled minibody (Zr-89 Df-Crefmirlimab) designed to bind to human CD8 T-cell receptors for quantitative PET imaging of tumors in cancer patients. The radiotracer will be used initially in third party-sponsored clinical trials, with the goal of achieving market authorization.
Under the terms of the deal, ImaginAb will receive a license fee and will be entitled to receive potential milestone payments and double-digit royalties on its CD8 immuno-PET products. No other terms were disclosed.